M
Maze Therapeutics, Inc. (MAZE)
NGM – Real vaqt narxi. Valyuta: USD
28.43
+1.41 (5.22%)
Yopilishda: Jun 26, 2026, 4:00 PM EDT
28.99
+0.56 (1.97%)
Bozordan keyin: Jun 26, 2026, 6:16 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NGM – Real vaqt narxi. Valyuta: USD
28.43
+1.41 (5.22%)
Yopilishda: Jun 26, 2026, 4:00 PM EDT
28.99
+0.56 (1.97%)
Bozordan keyin: Jun 26, 2026, 6:16 PM EDT
Maze Therapeutics, Inc. klinik bosqichdagi biofarmatsevtika kompaniyasi bo'lib, Qo'shma Shtatlarda buyrak va metabolik kasalliklarni davolash uchun kichik molekulali aniq dori vositalarini ishlab chiqadi. Uning asosiy dasturlari quyidagilarni o'z ichiga oladi: MZE829, og'iz orqali qabul qilinadigan apolipoprotein L1, yoki APOL1 ingibitori, APOL1 buyrak kasalligi bilan og'rigan bemorlarni davolash uchun II bosqich klinik sinovida; va MZE782, og'iz orqali qabul qilinadigan kichik molekulali ingibitor, fenilketonuriya va surunkali buyrak kasalligini davolash uchun II bosqichga tayyor klinik sinovda. Kompaniya, shuningdek, Pompe kasalligini davolash uchun mushaklarga xos glikogen sintaza ingibitorining tadqiqot dasturi bo'lgan MZE001ni ishlab chiqadi. Kompaniya Trace Neuroscience, Inc. bilan UNC13A ni aniqlash bo'yicha tadqiqot dasturi uchun; Shionogi & Co., Ltd. bilan MZE001ni tadqiq qilish, ishlab chiqish, ishlab chiqarish va tijoratlashtirish uchun; va Neurocrine Biosciences, Inc. bilan ATXN2 ni aniqlash bo'yicha tadqiqot dasturi uchun litsenzion shartnomaga ega. Kompaniya ilgari Modulus Therapeutics, Inc. nomi bilan tanilgan va 2018 yil sentyabr oyida Maze Therapeutics, Inc. nomini olgan. Kompaniya 2017 yilda tashkil etilgan va Janubiy San-Frantsisko, Kaliforniyada joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Harold S. Bernstein M.D., Ph.D. | President of Research & Development and Chief Medical Officer |
| Dr. Jason V. Coloma M.B.A., M.P.H., Ph.D. | CEO & Director |
| Mr. Atul Dandekar | Chief Strategy & Business Officer |
| Mr. Maarten Hoek | Senior Vice President of Research |
| Mr. Matt Krause | Senior Vice President of Human Resources |
| Mr. Misbah Tahir CPA | CFO & Principal Accounting Officer |
| Mr. Vipin Vijayakumar | Vice President of R&D Infrastructure and Operations |
| Mr. Winston Tse | Senior Vice President of Drug Discovery |
| Ms. Courtney J. Phillips J.D. | General Counsel & Corporate Secretary |
| Ms. Nazila Habibizad | Senior Vice President of Technical Operations & Supply Chain |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-06-10 | 8-K | d110541d8k.htm |
| 2026-05-22 | 8-K | d909749d8k.htm |
| 2026-05-12 | POS AM | d89432dposam.htm |
| 2026-05-12 | 8-K | maze-20260512.htm |
| 2026-05-12 | 10-Q | maze-20260331.htm |
| 2026-04-28 | DEFA14A | ef20071648_defa14a.htm |
| 2026-04-28 | DEF 14A | ef20071652_def14a.htm |
| 2026-04-28 | ARS | ef20071733_ars.pdf |
| 2026-04-22 | 8-K | d115741d8k.htm |
| 2026-03-25 | 8-K | maze-20260324.htm |